News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Lipodystrophy
Health Canada rejects tesamorelin for lipodystrophy

After consideration of the NDS, Health Canada decided that the risks of tesamorelin outweighed its benefits under the proposed conditions of use.

Published
13 March 2013
From
Theratechnologies press release
The search for a cure
Gene therapy studies show potential for HIV control without drugs

Gene therapy approaches that involve the genetic modification of human haematopoietic stem cells have the potental to engineer HIV control by introducing cells resistant to

Published
13 March 2013
By
Gus Cairns
Microbicides
Bee Venom Destroys HIV And Spares Surrounding Cells

Nanoparticles containing bee venom toxin melittin can destroy human immunodeficiency virus (HIV) while at the same time leaving surrounding cells unharmed, scientists from Washington University School of Medicine reported in the March 2013 issue of Antiviral Therapy.

Published
10 March 2013
From
HIV / AIDS News From Medical News Today
Treatment-experienced people
New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy

The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for treatment-experienced people with resistance to two or more antiretroviral drug classes, researchers reported in a poster

Published
10 March 2013
By
Liz Highleyman
Finance and funding
Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011

The latest report found US$2.6 billion was invested in HIV treatment R&D in 2011. Data from 41 public, private, and philanthropic donors reveal a 12% increase in funding from the baseline year of 2009, with the majority of funding targeted at research for new medications.

Published
07 March 2013
From
Treatment Action Group
New and experimental HIV treatments
Can people with resistant HIV omit NRTIs when switching from a failing regimen?

Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least two active agents can reduce pill burden and

Published
07 March 2013
By
Liz Highleyman
New and experimental HIV treatments
New pro-drug tenofovir alafenamide appears equally effective but better tolerated

Tenofovir alafenamide fumarate or TAF (formerly GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells harbouring HIV more easily than the older tenofovir disoproxil

Published
07 March 2013
By
Liz Highleyman
New and experimental HIV treatments
New NNRTI MK-1439 shows promise in early clinical trial

A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated robust antiretroviral activity and good tolerability as monotherapy in a small phase Ib clinical study, researchers reported yesterday at the

Published
06 March 2013
By
Liz Highleyman
New and experimental HIV treatments
Dual CCR5/CCR2 inhibitor cenicriviroc has anti-inflammatory as well as anti-HIV effect

Cenicriviroc, which blocks both CCR5 and CCR2 receptors on immune cells, is effective against HIV, better tolerated than current antiretrovirals and has immunomodulatory activity that may reduce inflammation,

Published
06 March 2013
By
Liz Highleyman
Pharmaceutical industry
GSK wins priority status for new HIV drug in US

U.S. regulators gave priority review status to an experimental GlaxoSmithKline drug for HIV/AIDS, which industry analysts view as a possible multibillion-dollar-a-year seller.

Published
18 February 2013
From
Reuters
← First12345...66Next →

Filter by country